SCHEMBL5862012

SCHEMBL5862012

COc1ccccc1-c1ccc(Cc2c(C)c(OC)c(OC)c(OC)c2OC)cc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.43
EIF4E P06730 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42
TUBA1C Q9BQE3 1/20 0.42
TUBB6 Q9BUF5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859880 0.90 HTR7 (0.42) KDM4EALDH1A1HPGDHSD17B10TUBB4A
SCHEMBL5859262 0.87 FOLH1 (0.52) FOLH1HSD17B10LPAR1SMN1; SMN2
SCHEMBL6095819 0.84 CFD (0.50) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL5859079 0.81 SMN1; SMN2 (0.59) FOLH1EIF4EKDM4EALDH1A1LPAR1
SCHEMBL6098146 0.81 KDM4E (0.48) FOLH1KDM4EALDH1A1HPGDLPAR1
SCHEMBL5858995 0.80 PTPN1 (0.43) FOLH1LPAR1SMN1; SMN2
SCHEMBL5859106 0.80 SMN1; SMN2 (0.48) FOLH1EIF4ETUBB4ATUBBTUBA3C
SCHEMBL5860287 0.80 FOLH1 (0.57) FOLH1KDM4EALDH1A1TDP1PTGER1
SCHEMBL5859840 0.80 SMN1; SMN2 (0.44) FOLH1EIF4EALDH1A1HSD17B10TUBB4A
SCHEMBL6095110 0.79 KLKB1 (0.58) ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122543-B2 Substituted benzoic acid derivatives having NF-κB inhibiting action DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-10-17 US disclosed
EP-1437339-A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-07-14 EP disclosed
CN-1505603-A Substituted benzoic ac id derivatives exhibiting nf-kappab inhibiting activity ��һ��������ҩ��ʽ���� 2004-06-16 CN disclosed
US-20040039061-A1 Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039061-A1 Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity NFKBIA, NFKB2, IKBKB FOLH1 4276/4885EIF4E 2243/4885KDM4E 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.